Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Sees Large Growth in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 2,067,445 shares, an increase of 56.8% from the September 15th total of 1,318,893 shares. Currently, 8.6% of the shares of the company are short sold. Based on an average daily trading volume, of 569,389 shares, the short-interest ratio is currently 3.6 days.

Analyst Ratings Changes

FTH has been the subject of several recent research reports. William Blair started coverage on shares of Sensei Biotherapeutics in a research report on Friday. They set an “outperform” rating for the company. Robert W. Baird began coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price target on the stock. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Finally, Guggenheim assumed coverage on Sensei Biotherapeutics in a research report on Wednesday, September 16th. They set a “buy” rating and a $70.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Price Performance

NASDAQ:FTH traded down $1.76 during midday trading on Friday, hitting $18.84. 58,405 shares of the company traded hands, compared to its average volume of 241,577. The firm has a fifty day moving average price of $31.50. The stock has a market cap of $486.83 million, a price-to-earnings ratio of -0.13 and a beta of -0.29. Sensei Biotherapeutics has a 12-month low of $7.45 and a 12-month high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. On average, analysts anticipate that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in shares of Sensei Biotherapeutics in the second quarter worth approximately $307,000. Renaissance Technologies LLC lifted its stake in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Stempoint Capital LP purchased a new position in Sensei Biotherapeutics during the 1st quarter valued at $4,188,000. Finally, Alyeska Investment Group L.P. purchased a new position in Sensei Biotherapeutics during the 2nd quarter valued at $3,610,000. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.